About GENA
At GENA, we are dedicated to revolutionizing the healthcare and genomics industries through innovative AI-based analytics. As a subsidiary of SIVOTEC, GENA focuses on making genetic testing more accessible, affordable, and efficient for labs, hospitals, health systems, and academic centers. Our mission is to accelerate diagnosis times, improve patient outcomes, and provide personalized care through cutting-edge technology.
Our Mission
Empowering healthcare with AI-driven genomic analysis, reducing diagnosis time from days to seconds.
At GENA™, we provide the most advanced tools for personalized, predictive care, transforming the way genetic data is analyzed and applied to improve outcomes worldwide.
Our Products
The GENA platform GENA’s features are designed to meet the needs of modern healthcare, with solutions including:
Each of these tools are available as a package or separately, built on the proprietary, AI-powered GENA platform, to empower healthcare professionals to deliver personalized care while generating valuable data for future advancements.
Expanding Beyond Genomics
While GENA’s roots are in genomics, our platform is evolving into a powerful system powered by a private language model (PLM) built specifically for healthcare. We are creating a secure, data-driven ecosystem that aggregates and analyzes multi-domain health data, with applications across pharmaceuticals, insurance, healthcare systems, and research. Our domain-tuned AI delivers contextual, real-time insights that empower providers and researchers to make faster, more informed decisions throughout the entire care journey.
Our Impact
Founded over 9 years ago, the GENA™ platform decreases the time spent on genomic analysis by 98%. GENA™ has already been used by more than 1,600 geneticists and has analyzed over 160,000 unique cases. Our Artificial Intelligence and Machine Learning genomics SaaS platform is the most widely used resource of its kind, supporting genomic labs in over 40 countries.
Commitment to Innovation
As part of Sivotec Bioinformatics, GENA leverages extensive expertise in AI, genomics, and data analytics to create products that are at the forefront of health technology. We are continually expanding our capabilities and developing new tools to support practitioners, labs, educational institutions, and healthcare institutions worldwide.
Executive Leadership Team
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Richard Simon is an experienced healthcare executive in the medical community. Richard served at Tenet as Physician Services Regional Director, Mednax Director of Operations, and National Director of Pediatric Cardiology. Richard now serves as COO at Sivotec, focusing on Marketing, Product & Operations.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Dr. Klaas Wierenga is a board-certified medical geneticist and medical biochemical geneticist at Mayo Clinic in Jacksonville, whose specialty is around clinical care to patients with or suspected to have genetic disorders. His research interests are focused on using information technology for diagnostics and gene discovery.
Dr. Klaas Wierenga is a board-certified medical geneticist and medical biochemical geneticist at Mayo Clinic in Jacksonville, whose specialty is around clinical care to patients with or suspected to have genetic disorders. His research interests are focused on using information technology for diagnostics and gene discovery.
Dr. Klaas Wierenga is a board-certified medical geneticist and medical biochemical geneticist at Mayo Clinic in Jacksonville, whose specialty is around clinical care to patients with or suspected to have genetic disorders. His research interests are focused on using information technology for diagnostics and gene discovery.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Board of Directors & Advisory Board
External Board of Directors & Advisory Board
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Executive Leadership Team
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Richard Simon is an experienced healthcare executive in the medical community. Richard served at Tenet as Physician Services Regional Director, Mednax Director of Operations, and National Director of Pediatric Cardiology. Richard now serves as COO at Sivotec, focusing on Marketing, Product & Operations.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Dr. Klaas Wierenga is a board-certified medical geneticist and medical biochemical geneticist at Mayo Clinic in Jacksonville, whose specialty is around clinical care to patients with or suspected to have genetic disorders. His research interests are focused on using information technology for diagnostics and gene discovery.
Dr. Klaas Wierenga is a board-certified medical geneticist and medical biochemical geneticist at Mayo Clinic in Jacksonville, whose specialty is around clinical care to patients with or suspected to have genetic disorders. His research interests are focused on using information technology for diagnostics and gene discovery.
Dr. Klaas Wierenga is a board-certified medical geneticist and medical biochemical geneticist at Mayo Clinic in Jacksonville, whose specialty is around clinical care to patients with or suspected to have genetic disorders. His research interests are focused on using information technology for diagnostics and gene discovery.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Board of Directors & Advisory Board
External Board of Directors & Advisory Board
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Dr. Rachel Burnside is a Scientific Advisor at GENA. A clinical cytogeneticist and industry leader, she brings over 15 years of experience in genomics, diagnostics, and product strategy. She is currently a professor at the University of Florida and previously held leadership roles at Bionano Genomics, Beckman Coulter, and LabCorp. Dr. Burnside’s work bridges research, clinical application, and commercial development in genomic medicine.
Dr. Rachel Burnside is a Scientific Advisor at GENA. A clinical cytogeneticist and industry leader, she brings over 15 years of experience in genomics, diagnostics, and product strategy. She is currently a professor at the University of Florida and previously held leadership roles at Bionano Genomics, Beckman Coulter, and LabCorp. Dr. Burnside’s work bridges research, clinical application, and commercial development in genomic medicine.
Dr. Rachel Burnside is a Scientific Advisor at GENA. A clinical cytogeneticist and industry leader, she brings over 15 years of experience in genomics, diagnostics, and product strategy. She is currently a professor at the University of Florida and previously held leadership roles at Bionano Genomics, Beckman Coulter, and LabCorp. Dr. Burnside’s work bridges research, clinical application, and commercial development in genomic medicine.
Dr. Rachel Burnside is a Scientific Advisor at GENA. A clinical cytogeneticist and industry leader, she brings over 15 years of experience in genomics, diagnostics, and product strategy. She is currently a professor at the University of Florida and previously held leadership roles at Bionano Genomics, Beckman Coulter, and LabCorp. Dr. Burnside’s work bridges research, clinical application, and commercial development in genomic medicine.
Get Started with GENA
At GENA, we believe in fostering collaboration across the healthcare ecosystem. By joining our network, you’ll gain access to powerful tools, expert insights, and a growing community of practitioners dedicated to transforming healthcare through data-driven solutions.
Get in Touch
Discover how GENA is shaping the future of healthcare through AI-powered genomics and data analytics. Together, we can unlock the potential of personalized medicine and bring better care to all.